CN101022812A - 固体和晶体伊班膦酸钠及其制备方法 - Google Patents

固体和晶体伊班膦酸钠及其制备方法 Download PDF

Info

Publication number
CN101022812A
CN101022812A CNA2005800285039A CN200580028503A CN101022812A CN 101022812 A CN101022812 A CN 101022812A CN A2005800285039 A CNA2005800285039 A CN A2005800285039A CN 200580028503 A CN200580028503 A CN 200580028503A CN 101022812 A CN101022812 A CN 101022812A
Authority
CN
China
Prior art keywords
sodium
ibandronate
diffraction pattern
peaks
ray powder
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
CNA2005800285039A
Other languages
English (en)
Chinese (zh)
Inventor
R·利夫什茨-利伦
T·拜尔
J·阿伦希姆
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Teva Pharmaceutical Industries Ltd
Original Assignee
Teva Pharmaceutical Industries Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=35968334&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=CN101022812(A) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Teva Pharmaceutical Industries Ltd filed Critical Teva Pharmaceutical Industries Ltd
Publication of CN101022812A publication Critical patent/CN101022812A/zh
Pending legal-status Critical Current

Links

Images

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/66—Phosphorus compounds
    • A61K31/662—Phosphorus acids or esters thereof having P—C bonds, e.g. foscarnet, trichlorfon
    • A61K31/663—Compounds having two or more phosphorus acid groups or esters thereof, e.g. clodronic acid, pamidronic acid
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07F—ACYCLIC, CARBOCYCLIC OR HETEROCYCLIC COMPOUNDS CONTAINING ELEMENTS OTHER THAN CARBON, HYDROGEN, HALOGEN, OXYGEN, NITROGEN, SULFUR, SELENIUM OR TELLURIUM
    • C07F9/00—Compounds containing elements of Groups 5 or 15 of the Periodic Table
    • C07F9/02—Phosphorus compounds
    • C07F9/28—Phosphorus compounds with one or more P—C bonds
    • C07F9/38—Phosphonic acids [RP(=O)(OH)2]; Thiophosphonic acids ; [RP(=X1)(X2H)2(X1, X2 are each independently O, S or Se)]
    • C07F9/3804—Phosphonic acids [RP(=O)(OH)2]; Thiophosphonic acids ; [RP(=X1)(X2H)2(X1, X2 are each independently O, S or Se)] not used, see subgroups
    • C07F9/3839—Polyphosphonic acids
    • C07F9/3873—Polyphosphonic acids containing nitrogen substituent, e.g. N.....H or N-hydrocarbon group which can be substituted by halogen or nitro(so), N.....O, N.....S, N.....C(=X)- (X =O, S), N.....N, N...C(=X)...N (X =O, S)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
    • A61P19/10—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease for osteoporosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Animal Behavior & Ethology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Rheumatology (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Molecular Biology (AREA)
  • Biochemistry (AREA)
  • Epidemiology (AREA)
  • Diabetes (AREA)
  • Hematology (AREA)
  • Obesity (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Analysing Materials By The Use Of Radiation (AREA)
  • Liquid Crystal Substances (AREA)
  • Battery Electrode And Active Subsutance (AREA)
  • Crystals, And After-Treatments Of Crystals (AREA)
  • Artificial Filaments (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
  • Secondary Cells (AREA)
  • Silicates, Zeolites, And Molecular Sieves (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
CNA2005800285039A 2004-08-23 2005-08-23 固体和晶体伊班膦酸钠及其制备方法 Pending CN101022812A (zh)

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
US60402604P 2004-08-23 2004-08-23
US60/604,026 2004-08-23
US69086705P 2005-06-16 2005-06-16
US60/690,867 2005-06-16
PCT/US2005/030500 WO2006024024A2 (en) 2004-08-23 2005-08-23 Solid and crystalline ibandronate sodium and processes for preparation thereof

Publications (1)

Publication Number Publication Date
CN101022812A true CN101022812A (zh) 2007-08-22

Family

ID=35968334

Family Applications (1)

Application Number Title Priority Date Filing Date
CNA2005800285039A Pending CN101022812A (zh) 2004-08-23 2005-08-23 固体和晶体伊班膦酸钠及其制备方法

Country Status (12)

Country Link
US (1) US7563918B2 (enExample)
EP (2) EP1713489B1 (enExample)
JP (1) JP4559431B2 (enExample)
KR (2) KR20070043043A (enExample)
CN (1) CN101022812A (enExample)
AT (2) ATE520406T1 (enExample)
CA (1) CA2576659A1 (enExample)
DE (2) DE602005025977D1 (enExample)
ES (1) ES2358269T3 (enExample)
IL (1) IL181298A (enExample)
PT (2) PT1713489E (enExample)
WO (1) WO2006024024A2 (enExample)

Cited By (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2008131160A1 (en) * 2007-04-19 2008-10-30 Dr. Reddy's Laboratories Ltd. Ibandronate sodium polymorphs
CN101111505B (zh) * 2005-02-01 2011-09-14 霍夫曼-拉罗奇有限公司 伊班膦酸盐多晶型物b
CN101111504B (zh) * 2005-02-01 2011-12-21 霍夫曼-拉罗奇有限公司 伊班膦酸盐多晶型物a

Families Citing this family (25)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
PT1663182E (pt) 2003-09-12 2013-03-14 Amgen Inc Formulação de dissolução rápida de cinacalcet hcl
WO2007074475A2 (en) * 2005-12-27 2007-07-05 Natco Pharma Limited Novel polymorphic forms of ibandronate
EP2046342A4 (en) * 2006-07-28 2011-05-04 Reddys Lab Ltd Dr CRYSTALLINE FORM WITH IBANDRONIC ACID AND PROCESS FOR PREPARING THE SAME
EP2009016A3 (en) 2006-11-16 2009-02-25 Teva Pharmaceutical Industries Ltd Process for preparing crystalline form of ibandronate sodium
CA2570949A1 (en) * 2006-12-12 2008-06-12 Apotex Pharmachem Inc. Ibandronate sodium propylene glycol solvate and processes for the preparation thereof
DK2144919T3 (en) 2007-04-11 2015-12-14 Hoffmann La Roche The multistage SYNTHESIS OF Ibandronate
US20090042839A1 (en) * 2007-08-09 2009-02-12 Sharon Avhar-Maydan Crystalline forms of ibandronate sodium
ES2428699T3 (es) * 2007-10-26 2013-11-08 Chemo Ibérica, S.A. Formas polimórficas de ibandronato de sodio y procedimientos para la preparación del mismo
EP2128166A1 (en) 2008-05-20 2009-12-02 Chemo Ibérica, S.A. Polymorphic forms of Ibandronate sodium and processes for preparation thereof
WO2009061336A1 (en) * 2007-11-05 2009-05-14 Teva Pharmaceutical Industries Ltd. Amorphous and crystalline forms of ibandronate disodium
EP2180003A1 (en) 2008-10-21 2010-04-28 Zentiva, k.s. Preparation of ibandronate trisodium
LT2395983T (lt) 2009-02-13 2020-07-10 Boehringer Ingelheim International Gmbh Farmacinė kompozicija, apimanti sglt2 inhibitorių, dpp-iv inhibitorių ir, pasirinktinai, papildomą priešdiabetinį agentą, bei jos panaudojimas
WO2010131267A1 (en) 2009-05-15 2010-11-18 Nox Medical System and methods using flexible capacitive electrodes for measuring biosignals
WO2011016738A1 (en) 2009-08-05 2011-02-10 Zaklady Farmaceutyczne Polpharma Sa A process for the synthesis of 1-hydroxy-3-(n-methylpentylamino) propylidene bisphosphonic acid monosodium salt, monohydrate
PT3494972T (pt) 2010-01-27 2024-02-12 Viiv Healthcare Co Combinações de dolutegravir e lamivudina para o tratamento de infeção pelo hiv
ES2525844T3 (es) 2010-06-25 2014-12-30 Nox Medical Ehf. Conector para correa biométrica
CN103957931B (zh) 2010-09-03 2017-10-24 瓦尔内瓦奥地利有限责任公司 艰难梭状芽胞杆菌毒素a和毒素b蛋白的分离多肽及其用途
UY33937A (es) 2011-03-07 2012-09-28 Boehringer Ingelheim Int Composiciones farmacéuticas que contienen inhibidores de dpp-4 y/o sglt-2 y metformina
WO2013179305A1 (en) * 2012-06-01 2013-12-05 Hetero Research Foundation Ibandronate sodium solid dispersion
EP2981532A4 (en) 2013-04-01 2016-12-14 Hetero Research Foundation PROCESS FOR THE PREPARATION OF POMALIDOMIDE
WO2015068041A1 (en) 2013-11-06 2015-05-14 Nox Medical Method, apparatus, and system for measuring respiratory effort
TWI846166B (zh) 2013-11-15 2024-06-21 美商阿克比治療有限公司 {[5-(3-氯苯基)-3-羥基吡啶-2-羰基]胺基}乙酸之固體型式，其組合物及用途
US10869619B2 (en) 2016-08-19 2020-12-22 Nox Medical Method, apparatus, and system for measuring respiratory effort of a subject
WO2018220606A1 (en) 2017-06-02 2018-12-06 Nox Medical Ehf Coherence-based method, apparatus, and system for identifying corresponding signals of a physiological study
EP3678543A1 (en) 2017-09-08 2020-07-15 Nox Medical System and method for non-invasively determining an internal component of respiratory effort

Family Cites Families (22)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE3623397A1 (de) * 1986-07-11 1988-01-14 Boehringer Mannheim Gmbh Neue diphosphonsaeurederivate, verfahren zu deren herstellung und diese verbindungen enthaltende arzneimittel
JP2639721B2 (ja) 1988-12-27 1997-08-13 富士重工業株式会社 内燃機関の燃焼室
US5652227A (en) * 1995-01-30 1997-07-29 Teronen; Olli Pekka Inhibition of the degradation of connective tissue matrix protein components in mammals
DE19637890A1 (de) * 1996-09-17 1998-03-19 Max Planck Gesellschaft Biphosphonat-Liposomen
DE19828450A1 (de) * 1998-06-26 1999-12-30 Hassan Jomaa Bisphosphonsäuren und deren Derivate enthaltende Arzneimittel zur Prophylaxe und zur Behandlung von Autoimmunkrankheiten sowie von Allergien
EP0998933A1 (de) * 1998-10-09 2000-05-10 Boehringer Mannheim Gmbh Verfahren zur Herstellung von bisphosphonathaltigen pharmazeutischen Zusammensetzungen zur oralen Applikation
EP0998932A1 (de) * 1998-10-09 2000-05-10 Boehringer Mannheim Gmbh Feste pharmazeutische Darreichungsform enthaltend Diphosphonsäure oder deren Salze und Verfahren zu ihrer Herstellung
NZ515541A (en) * 1999-05-21 2003-03-28 Novartis Ag Pharmaceutical compositions comprising bisphosphonates to treat angiogenesis
US6677320B2 (en) * 2000-01-20 2004-01-13 Hoffmann-La Roches Inc. Parenteral bisphosphonate composition with improved local tolerance
AU778431B2 (en) * 2000-05-05 2004-12-02 F. Hoffmann-La Roche Ag Gel-like pharmaceutical composition for subcutaneous administration comprising bisphosphonic acids or their salts
DE60113537T3 (de) * 2000-06-20 2013-05-29 Novartis Ag Methode zur verabreichung von biphosphonaten
GB0029111D0 (en) * 2000-11-29 2001-01-10 Novartis Ag Organic compounds
MXPA02001219A (es) * 2001-02-01 2005-06-06 Riderway Corp Composicion farmaceutica liquida para el tratamiento de enfermedades oseas.
ITMI20020908A1 (it) 2002-04-29 2003-10-29 Chemi Spa Processo di preparazione di sodio alendronato
DE60317061T2 (de) * 2002-05-10 2008-07-24 F. Hoffmann-La Roche Ag Ibandronsäure zur behandlung und vorbeugung von osteoporose
MXPA04011337A (es) * 2002-05-17 2005-07-01 Wyeth Corp Portadores de acido hialuronico solidos y susceptibles de ser inyectados para la liberacion de proteinas osteogenicas.
EP1596870B2 (en) * 2002-12-20 2011-04-06 F. Hoffmann-La Roche AG High dose ibandronate formulation
DE602004032577D1 (de) * 2003-12-23 2011-06-16 Alchymars S P A Amorphe Form das Natriumsalzes der Ibandronsäure
MX2007000087A (es) * 2004-06-23 2007-11-06 Teva Pharma Acido ibandronico solido y cristalino.
PT2662380T (pt) 2005-02-01 2019-02-27 Atnahs Pharma Uk Ltd Utilização médica de polimorfo a de ibandronato
MX2007008917A (es) 2005-02-01 2007-08-21 Hoffmann La Roche Polimorfo b de ibandronato.
WO2007074475A2 (en) 2005-12-27 2007-07-05 Natco Pharma Limited Novel polymorphic forms of ibandronate

Cited By (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN101111505B (zh) * 2005-02-01 2011-09-14 霍夫曼-拉罗奇有限公司 伊班膦酸盐多晶型物b
CN101111504B (zh) * 2005-02-01 2011-12-21 霍夫曼-拉罗奇有限公司 伊班膦酸盐多晶型物a
WO2008131160A1 (en) * 2007-04-19 2008-10-30 Dr. Reddy's Laboratories Ltd. Ibandronate sodium polymorphs

Also Published As

Publication number Publication date
US20070179119A1 (en) 2007-08-02
KR20090120011A (ko) 2009-11-23
DE602005025977D1 (de) 2011-03-03
ATE495747T1 (de) 2011-02-15
PT1713489E (pt) 2011-03-03
ATE520406T1 (de) 2011-09-15
EP1930011B1 (en) 2011-08-17
DE202005021414U1 (de) 2008-03-20
US7563918B2 (en) 2009-07-21
IL181298A (en) 2011-04-28
EP1930011A2 (en) 2008-06-11
JP2007512237A (ja) 2007-05-17
EP1713489B1 (en) 2011-01-19
WO2006024024A3 (en) 2006-06-29
CA2576659A1 (en) 2006-03-02
PT1930011E (pt) 2011-09-16
WO2006024024A2 (en) 2006-03-02
EP1930011A3 (en) 2008-06-18
IL181298A0 (en) 2007-07-04
ES2358269T3 (es) 2011-05-09
JP4559431B2 (ja) 2010-10-06
EP1713489A2 (en) 2006-10-25
KR20070043043A (ko) 2007-04-24

Similar Documents

Publication Publication Date Title
CN101022812A (zh) 固体和晶体伊班膦酸钠及其制备方法
EP2426104A1 (en) Tigecycline crystalline form and process for preparation thereof
CN101939303B (zh) 波生坦的晶型
KR20080032031A (ko) Ｏ-데스메틸벤라팍신의 결정형
JP2009524685A (ja) ９−ヒドロキシ−リスペリドン（パリペリドン）の結晶型
WO2020014406A1 (en) Solid state forms of omecamtiv mecarbil & omecamtiv mecarbil dihcl
JP2006249105A (ja) ゾルピデムヘミタートレイト
CN115515941A (zh) Mavacamten的固态形式及其制备工艺
KR20080055990A (ko) 시나칼셋 ＨＣｌ의 결정형 및 이의 제조 방법
KR20080022595A (ko) 지프라시돈 ＨＣｌ의 다형 형태 및 그 제조 방법
CN101472878A (zh) O-去甲基文拉法辛晶型
CN101421284A (zh) 伊班膦酸的结晶形式和其制备方法
CN1950331A (zh) 那格列奈的多晶型物
ES2368663T3 (es) Forma cristalina del ibandronato sódico.
CN115581118A (zh) 制造结晶形式的2-[(4s)-8-氟-2-[4-(3-甲氧基苯基)哌嗪-1-基]-3-[2-甲氧基-5-(三氟甲基)苯基]-4h-喹唑啉-4-基]乙酸钠三水合物的方法
CN1674902A (zh) 新晶型的加替沙星
KR20070088507A (ko) 카베딜올의 결정질 형태 및 이것의 제조 방법
MX2007002286A (en) Solid and crystalline ibandronate sodium and processes for preparation thereof

Legal Events

Date Code Title Description
C06 Publication
PB01 Publication
C10 Entry into substantive examination
SE01 Entry into force of request for substantive examination
C02 Deemed withdrawal of patent application after publication (patent law 2001)
WD01 Invention patent application deemed withdrawn after publication

Open date: 20070822